FRIDAY, Oct. 25, 2024 — Expanding Medicaid is associated with an increase in receipt of guideline-concordant treatment among nonelderly women newly diagnosed with hormone receptor (HR)-negative, human epidermal growth factor receptor 2…Original Article
Medicaid Expansion Increases Guideline-Concordant Treatment for Breast Cancer
FRIDAY, Oct. 25, 2024 — Expanding Medicaid is associated with an increase in receipt of guideline-concordant treatment among nonelderly women newly diagnosed with hormone receptor (HR)-negative, human epidermal growth factor receptor 2…
